Trial Profile
A Pilot Study to Evaluate the Feasibility of the Combined Use of Stereotactic Radiosurgery With Nivolumab and Concurrent Valproate in Patients With Recurrent Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Valproate
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 26 May 2017 Status changed from recruiting to discontinued because the pharmaceutical company (BMS) would no longer provide nivolumab for the study
- 06 May 2016 Status changed from not yet recruiting to recruiting.
- 12 Jan 2016 New trial record